Dr. Kumar on Managing Toxicities in the MLN9708 Study

Shaji K. Kumar, MD
Published: Sunday, Dec 09, 2012

Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, talks about managing toxicities in the MLN9708 study.

Kumar was the lead author on a phase I/II study analyzing MLN9708 in combination with lenalidomide and dexamethasone in previously untreated multiple myeloma patients. The study found that the recommended phase II dose showed antitumor activity and was well tolerated, with one peripheral neuropathy.

In most treatments, Kumar says, the main way to manage toxicity is to decrease the dosage. In the two patients that experienced peripheral neuropathy in the trial, their dosage was decreased and their condition improved.

<<< View coverage from the 2012 ASH Meeting

Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, talks about managing toxicities in the MLN9708 study.

Kumar was the lead author on a phase I/II study analyzing MLN9708 in combination with lenalidomide and dexamethasone in previously untreated multiple myeloma patients. The study found that the recommended phase II dose showed antitumor activity and was well tolerated, with one peripheral neuropathy.

In most treatments, Kumar says, the main way to manage toxicity is to decrease the dosage. In the two patients that experienced peripheral neuropathy in the trial, their dosage was decreased and their condition improved.

<<< View coverage from the 2012 ASH Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x